SGK1 expression predicts treatment response in paediatric medulloblastoma

We have recently demonstrated that genomic aberrations in medulloblastoma provide powerful independent markers for risk stratification and that gains and losses of chromosome 6 define distinct subgroups of medulloblastoma patients (16% vs. 100% 5-year OS). To identify genes affected by aberrations of chromosome 6, we performed genome-wide mRNA expression profiling and array-CGH for 47 medulloblastoma samples. Additionally, SGK1 protein expression was determined by immunohistochemistry on a tissue-microarray representing a large independent patient cohort (n=260). Results of both studies were then correlated to c…